Article
Biology
Sridevi Challa, Keun W. Ryu, Amy L. Whitaker, Jonathan C. Abshier, Cristel Camacho, W. Lee Kraus
Summary: In this study, PAR Trackers were developed and characterized as highly sensitive tools for detecting ADPR in various experimental and biological systems, providing greater temporal and spatial precision.
Article
Biochemistry & Molecular Biology
Masato Mashimo, Akane Morozumi, Akari Nobeyama, Misato Kanzaki, Shigeru Negi, Jiro Kato, Joel Moss, Atsuo Nomura, Takeshi Fujii
Summary: Parthanatos is a programmed cell death process mediated by PARP1, which inhibits endocytosis by binding to Rab5, leading to cell starvation and death.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Emad Matanes, Vanessa M. Lopez-Ozuna, David Octeau, Tahira Baloch, Florentin Racovitan, Amandeep Kaur Dhillon, Roy Kessous, Oded Raban, Liron Kogan, Shannon Salvador, Susie Lau, Walter H. Gotlieb, Amber Yasmeen
Summary: The study showed that PARG inhibition can complement PARP inhibition in the treatment of ovarian cancer, especially in the presence of homologous recombination defects. PARG inhibitor alone or in combination with PARPi or Cisplatin can reduce cell migration and induce cell death.
FRONTIERS IN ONCOLOGY
(2021)
Article
Chemistry, Multidisciplinary
Min Jun Kim, Yong Hwa Hwang, Jin Wook Hwang, Zahid Alam, Dong Yun Lee
Summary: Heme oxygenase-1 (HO1) gene therapy can modulate intracellular molecules to inhibit the release of HMGB1, which in turn improves the efficiency of islet transplantation treatment.
JOURNAL OF CONTROLLED RELEASE
(2022)
Review
Oncology
Andrisha-Jade Inderjeeth, Monique Topp, Elaine Sanij, Elena Castro, Shahneen Sandhu
Summary: This article summarizes the treatment advances in metastatic prostate cancer and the use of PARP inhibitors. Approximately a quarter of advanced prostate cancer patients have alterations in DNA repair pathways, making them eligible for treatment with PARP inhibitors. PARP inhibitors can be used as monotherapy and in combination with other drugs, providing additional treatment benefits.
Article
Multidisciplinary Sciences
Johannes Rudolph, Genevieve Roberts, Karolin Luger
Summary: PARP1 and PARP2 are key enzymes in the DNA damage response. HPF1 plays an essential role in modulating the PARylation of histones by forming a complex with both PARP1 and PARP2. Results show how HPF1 can affect the binding affinity of certain inhibitors to PARP1.
NATURE COMMUNICATIONS
(2021)
Review
Chemistry, Medicinal
Arwa AlGhamdi, Hanine AlMubayedh
Summary: This report reviews the usage, drug design and development of PARPi from the past to present, current issues, and future plans.
MINI-REVIEWS IN MEDICINAL CHEMISTRY
(2022)
Article
Biochemistry & Molecular Biology
Keum-Young So, Seon-Hee Oh
Summary: Arsenic induces a distinctive cell death mode via PARP-1 activation in p53-deficient cells. This cell death is promoted by autophagy inhibition. These findings suggest that PARP-1 activation could be used as an effective therapeutic approach for arsenic toxicity in p53-deficient cells.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2023)
Review
Medicine, Research & Experimental
Komal Thapa, Heena Khan, Uma Sharma, Amarjot Kaur Grewal, Thakur Gurjeet Singh
Summary: This review discussed the role of PARP-1 in neurodegenerative diseases and various FDA-approved PARP-1 inhibitors. Studies have shown that targeting PARP with chemical inhibitors may have therapeutic outcomes in neurodegenerative diseases.
Article
Chemistry, Medicinal
Jeffrey W. Johannes, Amber Balazs, Derek Barratt, Michal Bista, Matthew D. Chuba, Sabina Cosulich, Susan E. Critchlow, Sebastien L. Degorce, Paolo Di Fruscia, Scott D. Edmondson, Kevin Embrey, Stephen Fawell, Avipsa Ghosh, Sonja J. Gill, Anders Gunnarsson, Sudhir M. Hande, Tom D. Heightman, Paul Hemsley, Giuditta Illuzzi, Jordan Lane, Carrie Larner, Elisabetta Leo, Lina Liu, Andrew Madin, Scott Martin, Lisa McWilliams, Mark J. O'Connor, Jonathan P. Orme, Fiona Pachl, Martin J. Packer, Xiaohui Pei, Andrew Pike, Marianne Schimpl, Hongyao She, Anna D. Staniszewska, Verity Talbot, Elizabeth Underwood, Jeffrey G. Varnes, Lin Xue, Tieguang Yao, Ke Zhang, Andrew X. Zhang, Xiaolan Zheng
Summary: PARP inhibitors have obtained regulatory approval in oncology for tumors with homologous recombination repair deficiency, including those with BRCA mutations. However, some inhibitors have failed in combination with first-line chemotherapies due to overlapping hematological toxicities. Current PARP inhibitors lack selectivity for PARP1, which may contribute to toxicity.
JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Biochemistry & Molecular Biology
Yuanjiang Wang, Kun Li, Wenqing Xu, Shaohua Gou
Summary: In this study, a series of novel PARP-1 inhibitors were designed and synthesized. Compound 19b and 19c exhibited stronger inhibitory activity and higher selectivity, with 19c showing superior sensitivity towards SK-OV-3 cells compared to Olaparib.
BIOORGANIC CHEMISTRY
(2023)
Editorial Material
Oncology
Keun-Yeong Jeong, Haejun Lee
Summary: Chemotherapeutic regimens for pancreatic cancer are limited as it is typically diagnosed in advanced stages and hard to detect early symptoms. Mutations in BRCA leading to reduced susceptibility to conventional chemotherapies offer a new perspective, emphasizing the key role of PARP-1 in genomic instability.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
(2021)
Review
Cell Biology
Jonathan Wooten, Nicole Mavingire, Katherine Damar, Andrea L. Perez, Eileen Brantley
Summary: Poly(ADP-ribose) polymerase 1 (PARP1) is involved in DNA repair mechanisms, and PARP inhibitors (PARPi) show synthetic lethality in malignancies with a deficiency in the homologous recombination (HR) pathway. Triple-negative breast cancer (TNBC) patients with HR mediator mutations, such as BRCA1 and BRCA2, can respond to PARPi. However, PARPi resistance is a common issue. This review discusses the roles of PARP in DNA repair, mechanisms of PARPi resistance in TNBC, and recent advances in overcoming PARPi resistance in TNBC.
JOURNAL OF CELLULAR PHYSIOLOGY
(2023)
Article
Cell Biology
Vijaya Prakash Krishnan Muthaiah, Kathiravan Kaliyappan, Supriya D. Mahajan
Summary: This study discovered that the DNA repair enzyme PARP1 plays a key role in the pathogenesis of neurodegenerative disorders. Inhibiting PARP1 to reduce oxidative stress can help recover damage in an in vitro model of blast injury using HEI-OC1 cells.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2023)
Article
Pharmacology & Pharmacy
Tingting Du, Zhihui Zhang, Jie Zhou, Li Sheng, Haiping Yao, Ming Ji, Bailing Xu, Xiaoguang Chen
Summary: YHP-836, a novel PARP inhibitor, demonstrates excellent inhibitory activity for both PARP1 and PARP2 enzymes and allosterically regulates them via DNA trapping. It shows cytotoxicity and induces cell cycle arrest in BRCA-mutated tumor cell lines, as well as sensitizes tumor cells to chemotherapy agents.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Yufeng Wang, Yibo Zhang, Tiffany Hughes, Jianying Zhang, Michael A. Caligiuri, Don M. Benson, Jianhua Yu
CLINICAL CANCER RESEARCH
(2018)
Article
Ophthalmology
Kazuhiro Tokuda, Byron Baron, Yasuhiro Kuramitsu, Takao Kitagawa, Nobuko Tokuda, Naoyuki Morishige, Masaaki Kobayashi, Kazuhiro Kimura, Kazuyuki Nakamura, Koh-Hei Sonoda
JAPANESE JOURNAL OF OPHTHALMOLOGY
(2018)
Article
Biochemistry & Molecular Biology
Yufeng Wang, Wenjuan Dong, Yibo Zhang, Michael A. Caligiuri, Jianhua Yu
Review
Genetics & Heredity
Vanessa Zammit, Byron Baron, Duncan Ayers
Article
Immunology
Hongwei Wang, Yibo Zhang, Xiaojin Wu, Yufeng Wang, Hanwei Cui, Xinxin Li, Jianying Zhang, Norman Tun, Yong Peng, Jianhua Yu
FRONTIERS IN IMMUNOLOGY
(2018)
Article
Immunology
Yufeng Wang, Yibo Zhang, Ping Yi, Wenjuan Dong, Ansel P. Nalin, Jianying Zhang, Zheng Zhu, Lichao Chen, Don M. Benson, Bethany L. Mundy-Bosse, Aharon G. Freud, Michael A. Caligiuri, Jianhua Yu
Article
Cell Biology
Kazuhiro Tokuda, Byron Baron, Chiemi Yamashiro, Yasuhiro Kuramitsu, Takao Kitagawa, Masaaki Kobayashi, Koh-Hei Sonoda, Kazuhiro Kimura
CELL BIOLOGY INTERNATIONAL
(2020)
Article
Multidisciplinary Sciences
Shajedul Islam, Takao Kitagawa, Byron Baron, Yoshihiro Abiko, Itsuo Chiba, Yasuhiro Kuramitsu
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a common form of pancreatic cancer with poor prognosis. Gene expression analysis identified 20 differentially expressed genes (DEGs) in PDAC tissues compared to non-cancerous tissues, enriched in extracellular matrix, cell adhesion, and protein-protein interaction pathways. Hub genes such as ITGA2, LAMB3, and LAMC2 play roles in PDAC progression and may serve as therapeutic targets.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Shajedul Islam, Takao Kitagawa, Byron Baron, Keisuke Kuhara, Hiroki Nagayasu, Masanobu Kobayashi, Itsuo Chiba, Yasuhiro Kuramitsu
Summary: AHCC(R) can reduce the expression levels of tumor-associated proteins in gemcitabine-resistant pancreatic cancer cells and inhibit cell migration, indicating its potential as a complementary therapeutic approach for pancreatic cancer.
Review
Obstetrics & Gynecology
Lorna Muscat Baron, Byron Baron
Summary: Pre-eclampsia is a serious pregnancy complication that can lead to significant morbidity and mortality in both mother and unborn foetus. Currently, only low dose aspirin is accepted as a preventive measure, so there is a need to identify reliable blood or urine biomarkers for non-invasive screening. Several DNA and protein molecules have been proposed as predictive markers for PE, but their reliability and reproducibility have been questioned. This review aims to evaluate the robustness of data gathered from various studies to better understand the link between the proposed biomarkers and the development of PE.
CURRENT WOMENS HEALTH REVIEWS
(2023)
Article
Surgery
Scott Custo, Byron Baron, Alex Felice, Elisa Seria
Summary: The study aimed to quantify and compare total protein and growth factor levels in three distinct platelet products, finding significant differences in protein retrieval and growth factor yield among them.
GMS INTERDISCIPLINARY PLASTIC AND RECONSTRUCTIVE SURGERY DGPW
(2022)
Review
Biochemistry & Molecular Biology
Isaac Micallef, Byron Baron
Summary: Research on colorectal cancer resistance mechanisms has shown that different signaling pathways, ABC transporters, and EMT contribute to chemotherapy failure, while dysregulation of miRNAs, lncRNAs, and circRNAs promotes resistance through various mechanisms. Understanding how these ncRNAs participate in chemoresistance can lead to solutions to overcome this problem in CRC.
Article
Oncology
Keisuke Kuhara, Takao Kitagawa, Byron Baron, Kazuhiro Tokuda, Kazuhiko Sakamoto, Hiroaki Nagano, Kazuyuki Nakamura, Masanobu Kobayashi, Hiroki Nagayasu, Yasuhiro Kuramitsu
Summary: This study identified LAP3 and PCK2 as potential factors responsible for maintaining encapsulation in HCC tissues through proteomic analysis.
CANCER GENOMICS & PROTEOMICS
(2021)
Review
Biochemistry & Molecular Biology
Gabriel Pisani, Byron Baron
Review
Biochemistry & Molecular Biology
Gabriel Pisani, Byron Baron
NON-CODING RNA RESEARCH
(2019)